CPG
ZVRA icon

Cornerstone Planning Group’s Zevra Therapeutics ZVRA Stock Holding History

Cornerstone Planning Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Hold
850
– – ﹤0.01% 881
2026
Q1 		$9.02K Buy
850
+150
+21% +$1.35K ﹤0.01% 923
2025
Q4 		$6.04K Buy
700
+697
+23,233% +$6.59K ﹤0.01% 927
2025
Q3 		$44 Buy
+3
New +$30 ﹤0.01% 1676

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cornerstone Planning Group's ZVRA Position: Q2 2026 in Review

Cornerstone Planning Group held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 850 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #881.

Cornerstone Planning Group first reported a position in ZVRA in Q3 2025 and has held it in 4 quarters since. 59 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Cornerstone Planning Group held 850 shares of Zevra Therapeutics worth $10.3K as of Q2 2026.
  • Cornerstone Planning Group left its Zevra Therapeutics share count unchanged in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #881 holding.
  • Cornerstone Planning Group first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 59 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.